Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8610
|
| pubmed:dateCreated |
1988-10-5
|
| pubmed:abstractText |
13,318 patients admitted to fifty-two coronary care units with suspected acute myocardial infarction were considered for inclusion in a double-blind study comparing recombinant tissue-type plasminogen activator (rt-PA) 100 mg plus heparin with placebo plus heparin. 8307 (62%) were excluded, mainly because their symptoms had begun more than 5 h previously, but all excluded patients were followed up at least until hospital discharge. 2516 patients were randomly allocated to rt-PA and 2495 to placebo. At one month the overall case fatality rates were 7.2% and 9.8%, respectively, a relative reduction of 26% (95% confidence interval 11-39%). 6.3% of patients given rt-PA had a bleeding complication (1.4% major) compared with 0.8% given placebo (0.4% major). However, the incidence of stroke was similar--1.1% in the rt-PA group and 1.0% in the placebo group. Subset analysis showed that patients who had a normal electrocardiogram (ECG) at the time of randomisation (17.5% of the whole trial population) had a low case fatality rate (1.6% in those given rt-PA compared with 3.0% in those given placebo). In those with an abnormal ECG at entry, rt-PA was associated with a 24.5% relative reduction in 1 month fatality (95% confidence interval 9-37%).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0140-6736
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
3
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
525-30
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2900919-Adolescent,
pubmed-meshheading:2900919-Adult,
pubmed-meshheading:2900919-Aged,
pubmed-meshheading:2900919-Cerebrovascular Disorders,
pubmed-meshheading:2900919-Clinical Trials as Topic,
pubmed-meshheading:2900919-Denmark,
pubmed-meshheading:2900919-Double-Blind Method,
pubmed-meshheading:2900919-Drug Administration Schedule,
pubmed-meshheading:2900919-Drug Evaluation,
pubmed-meshheading:2900919-Drug Therapy, Combination,
pubmed-meshheading:2900919-Electrocardiography,
pubmed-meshheading:2900919-Female,
pubmed-meshheading:2900919-Follow-Up Studies,
pubmed-meshheading:2900919-Great Britain,
pubmed-meshheading:2900919-Hemorrhage,
pubmed-meshheading:2900919-Heparin,
pubmed-meshheading:2900919-Humans,
pubmed-meshheading:2900919-Male,
pubmed-meshheading:2900919-Middle Aged,
pubmed-meshheading:2900919-Myocardial Infarction,
pubmed-meshheading:2900919-Norway,
pubmed-meshheading:2900919-Pregnancy,
pubmed-meshheading:2900919-Random Allocation,
pubmed-meshheading:2900919-Recombinant Proteins,
pubmed-meshheading:2900919-Sweden,
pubmed-meshheading:2900919-Time Factors,
pubmed-meshheading:2900919-Tissue Plasminogen Activator
|
| pubmed:year |
1988
|
| pubmed:articleTitle |
Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).
|
| pubmed:affiliation |
Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|